









Markets
/
Stocks
/
nasdaq-tlph
/

Talphera Inc

TLPH

0.850USD

-0.083-8.92%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

17.44MMarket Cap

LossP/E TTM



Talphera Inc

0.850

-0.083-8.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

85 / 175

Overall Ranking

254 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.167

Target Price

+346.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

Undervalued

The company’s latest PE is -2.14, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.96M shares, decreasing 6.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 81.36K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 12.05.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.14, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

6.56

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.11

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -2.35, which is -88.28% below the recent high of -0.28 and 49.17% above the recent low of -1.19.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Talphera Inc is 3.50, with a high of 6.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.167

Target Price

+390.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Talphera Inc

TLPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.63, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.27 and the support level at 0.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.63

Change

-1.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.027

Buy

RSI(14)

63.310

Neutral

STOCH(KDJ)(9,3,3)

42.699

Sell

ATR(14)

0.139

High Vlolatility

CCI(14)

29.195

Neutral

Williams %R

50.014

Neutral

TRIX(12,20)

3.557

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.936

Sell

MA10

0.914

Sell

MA20

0.727

Buy

MA50

0.549

Buy

MA100

0.521

Buy

MA200

0.559

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 33.93%, representing a quarter-over-quarter decrease of 1.93%. The largest institutional shareholder is The Vanguard, holding a total of 81.36K shares, representing 0.18% of shares outstanding, with 87.38% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rock Springs Capital Management LP

316.46K

Rosalind Advisors, Inc.

2.00M

+226.41%

Nantahala Capital Management, LLC

1.99M

Armistice Capital LLC

890.35K

-42.62%

Bleichroeder LP

426.62K

Angotti Vincent J

367.85K

+259.62%

Geode Capital Management, L.L.C.

165.61K

+1.47%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is -0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.